Victoria (Vicki) Demby is a global regulatory affairs consultant and the US Authorized regulatory Agent for Aminex Therapeutics, Inc. She possesses deep expertise in drug development and regulatory affairs, built through a progressive career in global regulatory roles at top pharmaceutical companies including Bristol Myers Squibb, Merck, and GlaxoSmithKline. Most recently, she held the position of Senior Vice President of Global Regulatory Affairs at Adlai Nortye, USA, Inc., where she was a member of the executive leadership team, leading the development and execution of global regulatory strategies across the company’s pipeline.
Throughout her career, Victoria has played a pivotal role in achieving regulatory approvals for a wide range of impactful therapies across diverse therapeutic areas. These include NULOJIX®, ORENCIA®, ELIQUIS®, MARIZEV®, JANUVIA®, JANUMET®, JANUMET XR®, and the landmark cancer immunotherapy KEYTRUDA®. She earned her Bachelor of Science in Biochemistry from the University of Vermont and completed her PhD in Pharmacology and Toxicology at the University of Kansas.